As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.
With Lumoxiti confirmed as commercially unviable monalizumab fails its phase 3 trial in head and neck cancer.
Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Venture capital has the brains, private equity has the books – can they make lots of money?